Welcome to today’s edition of The Armchair Analyst, a 5-minute daily update on the ASX life-sciences sector.
Sorry for the late send.
This morning, I kept refreshing my Comsec account for Tetratherix (ASX: TTX).
(My first ever Armchair Pick).
Up 30% so far, and hit an all-time high!
At one point, there were literally no sellers to be found:
If you want to read the full article, including why I invested in the company: My First Armchair Pick: Tetratherix (ASX: TTX).
Today, I want to do something a bit different. I want to put The Armchair Analyst under the microscope and explain some of my plans for the business and brand in 2026
But first…
The Pulse Check
Tetratherix (ASX: TTX) announces a new nasal delivery of peptides, hormones and GLP-1s and a 10-year R&D agreement with Superpower Health worth US$30M. (TTX)
🪑 Great announcement! First Armchair Pick.
Telix Pharmaceuticals (ASX: TLX) resubmits its New Drug Application to the FDA for its brain cancer imaging agent. (TLX)
Dimerix (ASX: DXB) will conduct a blinded statistical review of its Phase 3 disease trial. Results expected by April 2026. (DXB)
🪑 Took a trading position in this one two weeks ago, on the assumption that DXB would get closer to “accelerated approvals”. This blinded statistical review is the final step before application.
Arovella Therapeutics (ASX: ALA) announces TGA approval to proceed with the Phase 1 trial of ALA-101, an off-the-shelf cancer cell therapy program. (ALA)
🪑 Another trading position. I’ve still got these since my Christmas trade. Missed the opportunity to take profits at 10 cents. But will hold until Phase 1 starts at least.
PYC Therapeutics (ASX: PYC) has confirmed key endpoints of a registrational study and new drug application with the FDA for its precision medicine technology. (PYC)
BlinkLab (ASX: BB1) completes the final onboarding of the last site for its US pivotal study for FDA 510(k) approval of its autism detection and diagnosis product. (BB1)
🪑 Trial starts soon. The first patient is expected this month.
Racura Oncology (ASX: RAC) secures governance approval for the Phase 1 HARNESS-1 trial in non-small cell lung cancer patients. (RAC)
🪑 Milestone ticked.
Neurizon Therapeutics (ASX: NUZ) CEO Dr. Michael Thurn resigns. (NUZ)
Report: 2025 Data is in Diagnostics is having a Renaissance. (Health Advances)
🪑 Really great report, this one. Relevant for companies like RHY, BXD, COV, IIQ, MAP, PEB and PIQ.
Immutept (ASX: IMM) is trading up again today, around 6.5 cents.
🪑 For those who did the maths on the “true cash balance”. You would have done well to pick up stock at ‘peak fear’ at the 3-cent mark on Friday morning open.
Well done to my trader friends out there.
Cash Injection
Oneview Healthcare (ASX: ONE) secures A$19M placement at A$0.19 per share and launches a SPP to raise an additional A$2M. (ONE)
EMVision Medical Devices (ASX: EMV) receives a $3.8M R&D tax refund. (EMV)
Percheron Therapeutics (ASX: PER) announces a non-renounceable entitlement offer to raise up to $2.2 million at $0.005 per share. (PER)
Under the Microscope
Firstly, I want to thank you all.
For reading my content, for allowing me to do work I find meaningful, and for being part of the amazing Armchair Army.
Over the next 12 months, I want to build the Armchair Foundational Portfolio.
5 stocks. By invitation only.
This is how I intend to build the portfolio:
1x Company with a binary catalyst. High-risk, high-reward. (Even after Immutep, I am a sucker for pain)
2x Companies that I consider undervalued. Sub-$50M market cap companies that are either “growth” or “turnaround” stories.
1x Company in a hot macro thematic.
1x Wild card. Just something I like.
To keep the newsletter free, I offer a service to tell the stories of the stocks in the Armchair Portfolio to a retail audience.
I only take on 5 clients each year, and I take my fee in escrowed shares.
50% for six months, 50% for 12 months.
I don’t make money unless the stock goes up.
This makes me incredibly selective about the companies I choose.
Will I continue with the Biotech 165 Challenge?
Absolutely.
I set out a goal at the start of the year to meet with and cover all ASX-listed biotech and healthcare stocks.
It might take me a little longer than a year to make my way through all 165 listed companies…
But this is how I will choose which companies to crown in the portfolio.
My Transparency Guarantee to You
I value trust and transparency above anything else.
I guarantee that:
Every stock that I chose in the Armchair Portfolio is one that I truly believe in
I will never sell stock in a company in the Armchair Portfolio within 3 business days of posting content about them. I will hold per my escrow conditions (and very likely beyond).
I will make my portfolio public so you can see my holdings (and track my trades if you really want)... coming soon.
I’ll have an honest assessment of the risks and rewards for every company that I cover. If the news is bad, I’ll tell it like it is.
If you have any questions, please feel free to respond. I answer every email that comes through.
See you all tomorrow,
The Armchair Analyst
PS. I have an awesome guest post lined up tomorrow. The topic: How to evaluate a medtech’s US go-to-market strategy. Stay tuned.
